Responsiveness of a Balance Assessment Using a Mobile Application.

BACKGROUND: Balance assessment is used by clinicians as part of athlete concussion screening. The King-Devick (K-D) Balance app is designed to provide an objective balance assessment value. The purpose of this study was to investigate the responsiveness of a balance assessment using the K-D Balance app. HYPOTHESIS: The K-D Balance app will demonstrate acceptable responsiveness for balance assessment. STUDY DESIGN: Repeated-measures study. LEVEL OF EVIDENCE: Level 5. METHODS: A convenience sample of 25 participants between the ages of 20 and 25 years completed testing procedures. A battery of balance tests using the K-D Balance app on an iPhone were conducted 1 week apart. After a 5-minute warm-up, 3 stances were assessed: double leg, tandem right, and tandem left. The K-D Balance app guided the test positions and test times. A value representing movement was generated by the app algorithm. Analysis included descriptive statistics along with intraclass correlation coefficient and minimal detectable change (MDC). RESULTS: The median score of the K-D test was 0.5 for session 1 and 0.4 for session 2. The ICC was 0.42 (95% CI, 0.04-0.70), and the MDC was 1.58. CONCLUSION: The MDC value of 1.58 represents the threshold of meaningful change in balance, as measured with the K-D Balance app. CLINICAL RELEVANCE: Clinicians can use the results of this study to objectively assess changes in balance over time using the K-D Balance app.

Ice hockey summit II: zero tolerance for head hits and fighting.

OBJECTIVE: To present currently known basic science and on-ice influences of sport related concussion (SRC) in hockey, building upon the Ice Hockey Summit I action plan (2011) to reduce SRC. METHODS: The prior summit proceedings included an action plan intended to reduce SRC. As such, the proceedings from Summit I served as a point of departure, for the science and discussion held during Summit II (Mayo Clinic, Rochester MN, October, 2013). Summit II focused on Basic Science of Concussions in Ice Hockey: Taking Science Forward; (2) Acute and Chronic Concussion Care: Making a Difference; (3) Preventing Concussions via Behavior, Rules, Education and Measuring Effectiveness; (4) Updates in Equipment: their Relationship to Industry Standards and (5) Policies and Plans at State, National and Federal Levels to reduce SRC. Action strategies derived from the presentations and discussion described in these sectors were subsequently voted on for purposes of prioritization. The following proceedings include the knowledge and research shared by invited faculty, many of whom are health care providers and clinical investigators. RESULTS: The Summit II evidence based action plan emphasizes the rapidly evolving scientific content of hockey SRC. It includes the most highly prioritized strategies voted on for implementation to decrease concussion. CONCLUSIONS: The highest priority action items identified from the Summit include: 1) eliminate head hits from all levels of ice hockey, 2) change body checking policies, and 3) eliminate fighting in all amateur and professional hockey.

Ultrasound assessment of an acute biceps brachii injury.

The patient was a 24-year-old woman who was evaluated by a physical therapist in a direct-access sports medicine clinic for a chief complaint of right anterior arm pain and swelling. Given the unusual mechanism and location of the injury, significant pain and weakness, and questionable tissue defect, diagnostic ultrasound was ordered. The ultrasound examination findings revealed a strain of the right short head of the biceps brachii with a partial tear more distally.

Validity of hamstring muscle length assessment during the sit-and-reach test using an inclinometer to measure hip joint angle.

The aim of this study was twofold: (i) to describe the criterion-related validity of the sit-and-reach test (SRT) using a hand-held inclinometer when assessing hamstring muscle length (HML) when HML is recorded in degrees of hip joint angle (HJA); and (ii) to describe the effect of gender and age on HML in healthy adults during the performance of a SRT. We examined 212 healthy subjects (106 men and 106 women) whose ages ranged from 20 to 79 years. The Pearson-product moment correlation coefficient (r) described the relationship between HJA at the end-point of the SRT and the criterion, supine passive straight-leg raise (PSLR). We conducted a 6 x 2 analysis of variance, where age was stratified on 6 levels of 10-year increments (20-29, 30-39, 40-49, 50-59, 60-69, and 70-79 years of age) and gender was stratified on 2 levels (men and women). There was a statistically significant correlation (r = 0.59, P < 0.01) between performance on the SRT as measured by HJA and the supine PSLR, but the SRT only accounted for 35% of the variability in the PSLR. SRT performance in men (mean +/- SD, 80 +/- 9 degrees) was significantly less (P < 0.001) than in women (mean +/- SD, 92 +/- 10 degrees). Subjects in the 60- to 69- and 70- to 79-year age groups had significantly less (P < 0.05) HJA than those in the 20- to 29-, 30- to 39-, and 40- to 49-year age groups. Using an inclinometer to measure HJA during the SRT is not a valid method for assessing HML in men and women who can independently assume a long-sitting position on a hard surface. Clinicians should recognize there are differences in HML between men and women, and that men and women between 20 to 49 years of age have more HML than their counterparts between ages 60 to 79 years.

Economic effectiveness of disease management programs: a meta-analysis.

The economic effectiveness of disease management programs, which are designed to improve the clinical and economic outcomes for chronically ill individuals, has been evaluated extensively. A literature search was performed with MEDLINE and other published sources for the period covering January 1995 to September 2003. The search was limited to empirical articles that measured the direct economic outcomes for asthma, diabetes, and heart disease management programs. Of the 360 articles and presentations evaluated, only 67 met the selection criteria for meta-analysis, which included 32,041 subjects. Although some studies contained multiple measurements of direct economic outcomes, only one average effect size per study was included in the meta-analysis. Based on the studies included in the research, a meta-analysis provided a statistically significant answer to the question of whether disease management programs are economically effective. The magnitude of the observed average effect size for equally weighted studies was 0.311 (95% CI = 0.272-0.350). Statistically significant differences of effect sizes by study design, disease type and intensity of disease management program interventions were not found after a moderating variable, disease severity, was taken into consideration. The results suggest that disease management programs are more effective economically with severely ill enrollees and that chronic disease program interventions are most effective when coordinated with the overall level of disease severity. The findings can be generalized, which may assist health care policy makers and practitioners in addressing the issue of providing economically effective care for the growing number of individuals with chronic illness.

Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine.

Anidulafungin is a novel antifungal agent of the echinocandin class that is intended for the treatment of invasive fungal disease. It is likely that anidulafungin will be coadministered with cyclosporine. In vitro studies and clinical studies were performed to evaluate the effect of anidulafungin on cyclosporine metabolism and to investigate the safety and pharmacokinetics of anidulafungin when concomitantly administered with cyclosporine. The potential for anidulafungin to inhibit the metabolism of cyclosporine was evaluated by pooled human hepatic microsomal protein fractions in vitro, incubating 3H-cyclosporine with different concentrations of anidulafungin. The safety of coadministration and the effects of cyclosporine on the pharmacokinetics of anidulafungin were assessed in a multiple-dose, open-label clinical study of 12 healthy volunteers. Subjects received a 200-mg intravenous loading dose of anidulafungin, followed by a daily 100-mg intravenous maintenance dose on days 2 through 8. An oral solution of cyclosporine (Neoral oral solution; 100 mg/mL) 1.25 mg/kg was also administered to subjects twice daily on days 5 through 8. In the in vitro study, the addition of anidulafungin had no effect on cyclosporine metabolism by human hepatic microsomal protein fractions. In the clinical study, no dose-limiting toxicities or serious adverse events occurred. A small increase in anidulafungin concentrations and drug exposure (22%) was observed after 4 days of dosing with cyclosporine and was not considered to be clinically relevant. The results support the concomitant use of anidulafungin and cyclosporine without the need for dosage adjustments of either drug.

Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal.

The objective of this analysis was to describe the pharmacokinetic characteristics of anidulafungin in patients with serious fungal disease based on pharmacokinetic data collected during four recently completed or ongoing Phase II/III clinical studies. A total of 600 anidulafungin plasma samples from 225 patients across the four studies were available for analysis. Patients received daily intravenous infusions of 50, 75, or 100 mg anidulafungin, preceded by a loading dose that was twice the daily dose. The analysis population consisted of 129 patients with esophageal candidiasis, 87 with invasive candidiasis, 7 with invasive aspergillosis, and 2 with azole refractory mucosal candidiasis. A population analysis approach was used to develop a steady-state pharmacokinetic model for anidulafungin, assess the significance of possible covariates, and determine the amount of intersubject and random residual variability. A two-compartment model with first-order elimination provided the best fit to the data. The clearance of anidulafungin was influenced by weight and gender, and subjects in the invasive candidiasis study had a typical clearance that was approximately 30% higher than subjects from other studies. Weight was determined to be a predictor of the central volume of distribution. The covariates on clearance accounted for less than 20% of the intersubject variability and therefore are deemed to be of little clinical relevance. There was no evidence that the presence of rifampin or metabolic substrates, inhibitors, or inducers of cytochrome p450 influenced the clearance of anidulafungin. This indicates that dosing adjustments are not necessary when anidulafungin is administered in the presence of medications falling into these classifications.